BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 36332787)

  • 21. Pharmacotherapeutic advances for splenomegaly in myelofibrosis.
    Tremblay D; Mascarenhas J
    Expert Opin Pharmacother; 2023 Apr; 24(5):577-585. PubMed ID: 36922391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors.
    Duminuco A; Vetro C; Giallongo C; Palumbo GA
    Expert Opin Pharmacother; 2023; 24(13):1449-1461. PubMed ID: 37341682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Myelofibrosis: A Moving Target.
    Cerquozzi S; Farhadfar N; Tefferi A
    Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of myelofibrosis: JAK inhibition and beyond.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel therapeutics for myelofibrosis.
    Lee SE
    Blood Res; 2023 Apr; 58(S1):S13-S19. PubMed ID: 36891574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
    Chifotides HT; Bose P; Verstovsek S
    J Hematol Oncol; 2022 Jan; 15(1):7. PubMed ID: 35045875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
    Vaddi K; Sarlis NJ; Gupta V
    Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies.
    Naymagon L; Mascarenhas J
    Hemasphere; 2017 Dec; 1(1):e1. PubMed ID: 31723730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.
    Bose P
    Expert Opin Orphan Drugs; 2019; 7(10):415-425. PubMed ID: 33094033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
    Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
    Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. State-of-the-Art Review on Myelofibrosis Therapies.
    Wang F; Qiu T; Wang H; Yang Q
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
    Saleh K; Ribrag V
    Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.
    Verstovsek S; Mesa RA; Livingston RA; Hu W; Mascarenhas J
    J Hematol Oncol; 2023 Jul; 16(1):82. PubMed ID: 37501130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
    Winton EF; Kota V
    Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.
    Morsia E; Gangat N
    Expert Opin Ther Targets; 2021 Mar; 25(3):211-222. PubMed ID: 33844952
    [No Abstract]   [Full Text] [Related]  

  • 36. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
    Stein BL
    Leuk Lymphoma; 2023 Feb; 64(2):292-299. PubMed ID: 36301740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis.
    Duminuco A; Chifotides HT; Giallongo S; Giallongo C; Tibullo D; Palumbo GA
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment.
    Sastow D; Mascarenhas J; Tremblay D
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e507-e520. PubMed ID: 35221248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in pharmacotherapy for myelofibrosis: what is the current state of play?
    Tiribelli M; Morelli G; Bonifacio M
    Expert Opin Pharmacother; 2024 Apr; 25(6):743-754. PubMed ID: 38738513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Next Generation Therapeutics for the Treatment of Myelofibrosis.
    Tremblay D; Mascarenhas J
    Cells; 2021 Apr; 10(5):. PubMed ID: 33925695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.